GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » FCF Yield %

Solid Biosciences (Solid Biosciences) FCF Yield % : -26.08 (As of May. 16, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Solid Biosciences's Trailing 12-Month Free Cash Flow is $-95.70 Mil, and Market Cap is $352.10 Mil. Therefore, Solid Biosciences's FCF Yield % for today is -26.08%.

The historical rank and industry rank for Solid Biosciences's FCF Yield % or its related term are showing as below:

SLDB' s FCF Yield % Range Over the Past 10 Years
Min: -276.12   Med: -92.87   Max: -10.08
Current: -26.08


During the past 9 years, the highest FCF Yield % of Solid Biosciences was -10.08%. The lowest was -276.12%. And the median was -92.87%.

SLDB's FCF Yield % is ranked worse than
63.37% of 1556 companies
in the Biotechnology industry
Industry Median: -14.305 vs SLDB: -26.08

Solid Biosciences's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Solid Biosciences FCF Yield % Historical Data

The historical data trend for Solid Biosciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences FCF Yield % Chart

Solid Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only -47.45 -8.94 -40.94 -95.99 -76.45

Solid Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -134.34 -122.88 -106.64 -144.63 -66.83

Competitive Comparison of Solid Biosciences's FCF Yield %

For the Biotechnology subindustry, Solid Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solid Biosciences's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's FCF Yield % falls into.



Solid Biosciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Solid Biosciences's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-95.695 / 125.173724
=-76.45%

Solid Biosciences's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-20.913 * 4 / 125.173724
=-66.83%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solid Biosciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Solid Biosciences FCF Yield % Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Solid Biosciences (Solid Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Kevin Tan officer: CFO & Treasurer 20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot director, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
David T Howton officer: See Remarks VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jennifer Marlowe officer: CSO, FA & Cardiac 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Paul Herzich officer: Chief Technology Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan officer: Chief Regulatory Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Gabriel Brooks officer: Chief Medical Officer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris officer: Chief Scientific Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty director C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Clare Kahn director 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Bcls Sb Investco, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investo (gp), Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116

Solid Biosciences (Solid Biosciences) Headlines

From GuruFocus

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-08-2023